AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

9.900

-0.360-3.51%

Volume:108.62K

Turnover:1.09M

Market Cap:495.10M

PE:12.87

High:10.380

Open:10.380

Low:9.800

Close:10.260

Loading ...

Overview Company News Filings

Clinuvel Recruits 200 Patients in Phase Iii Vitiligo Trial Cuv105

THOMSON REUTERS

Clinuvel Pharmaceuticals Meets Recruitment Target in Phase 3 Scenesse Vitiligo Trial

MT Newswires Live

3 of the best small cap ASX stocks to buy now

Clinuvel Pharmaceuticals Ltd (CLVLF) (H1 2025) Earnings Call Highlights: Strong Revenue Growth ...

High Growth Tech Stocks To Watch In April 2025

Simply Wall St.

Clinuvel Pharmaceuticals to Buy Back Up to 1.5 Million Shares

MT Newswires Live

BRIEF-Clinuvel Pharmaceuticals Renews Share Buy-Back Program

Clinuvel Pharmaceuticals Ltd - Renews Share Buy-Back Program

THOMSON REUTERS

Clinuvel Pharmaceuticals Ltd - Repurchase of up to 1.5 Mln Ordinary Shares

THOMSON REUTERS

ASX Market Close: Index flirts with 8000 pts | March 26, 2025

The Market Herald

ASX Midday Sector Update: Materials Sector Soars, Healthcare Struggles

MT Newswires Live

Why Clinuvel, Orthocell, Vulcan, and Wildcat shares are storming higher

Clinuvel stroke drug shows ‘positive’ results – but some adverse effects left unclear

The Market Herald

Clinuvel Pharmaceuticals Reports Positive Study Results for Arterial Ischaemic Stroke Drug Candidate

MT Newswires Live

BRIEF-Clinuvel Pharmaceuticals Says CEO Philippe Wolgen To Take Temporary Leave

Clinuvel Pharmaceuticals' CEO to take Temporary Leave

MT Newswires Live

Clinuvel Pharmaceuticals Ltd - Lachlan Hay Appointed Acting CEO of Clinuvel

THOMSON REUTERS

High Growth Tech Stocks In Australia For March 2025

Simply Wall St.

Imugene Appoints CFO; Shares Fall 3%

MT Newswires Live

Clinuvel Pharmaceuticals Posts Higher Fiscal H1 Earnings, Revenue; Shares Up 8%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CUV.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":9.9,"timestamp":1748931120000,"preClose":10.26,"halted":0,"volume":108618,"delay":0,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41318955,"shares":50009750,"eps":0.769445,"marketStatus":"Not Yet Opened","change":-0.36,"latestTime":"06-03 16:12:00 AEST","open":10.38,"high":10.38,"low":9.8,"amount":1088033,"amplitude":0.05653,"askPrice":10.15,"askSize":5000,"bidPrice":9.85,"bidSize":1024,"shortable":3,"etf":0,"ttmEps":0.769445,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1748995200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":10.26,"dividendRate":0.005051,"openAndCloseTimeList":[[1748908800000,1748930400000]],"volumeRatio":1.243426161185297,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41318955,"roa":"14.22%","roe":"19.59%","lyrEps":0.7151,"volumeRatio":1.243426,"shares":50009750,"dividePrice":0.05,"high":10.38,"amplitude":0.05653,"preClose":10.26,"low":9.8,"week52Low":9.755,"pbRate":"2.28","psRate":"5.44","week52High":17.652,"institutionHeld":0,"latestPrice":9.9,"committee":-0.660027,"eps":0.769445,"divideRate":0.005051,"volume":108618,"delay":0,"ttmEps":0.769445,"open":10.38,"prevYearClose":12.06,"prevWeekClose":10.78,"prevMonthClose":10.78,"prevQuarterClose":11.46,"fiveDayClose":10.56,"twentyDayClose":11.3,"sixtyDayClose":12.05},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533644589","title":"Clinuvel Recruits 200 Patients in  Phase Iii Vitiligo Trial Cuv105","url":"https://stock-news.laohu8.com/highlight/detail?id=2533644589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533644589?lang=en_us&edition=fundamental","pubTime":"2025-05-07 12:10","pubTimestamp":1746591032,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nTUA1SVQYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2533616623","title":"Clinuvel Pharmaceuticals Meets Recruitment Target in Phase 3 Scenesse Vitiligo Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2533616623","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533616623?lang=en_us&edition=fundamental","pubTime":"2025-05-07 09:28","pubTimestamp":1746581315,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  has enrolled more than 200 patients in its phase III trial of Scenesse in vitiligo in line with its recruitment target, according to a Wednesday filing with the Australian bourse.The randomized trial is being conducted in 37 study sites across North America, Africa, and Europe. It is assessing Scenesse as a systemic repigmentation therapy for vitiligo patients using the vitiligo area scoring index as the primary endpoint, the filing said.The trial aims to achieve a minimum of 50% repigmentation across a patient's total body surface area, the filing added. Initial results are expected in the second half of 2026.Clinuvel Pharmaceuticals' shares were down nearly 1% in recent Wednesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2533562088","title":"3 of the best small cap ASX stocks to buy now","url":"https://stock-news.laohu8.com/highlight/detail?id=2533562088","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533562088?lang=en_us&edition=fundamental","pubTime":"2025-05-06 06:10","pubTimestamp":1746483006,"startTime":"0","endTime":"0","summary":"If you have a higher than average risk tolerance, then having a few small cap ASX stocks in a diversified portfolio could help take it to the next level. But which small cap ASX stocks could be among the best to buy now?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/06/3-of-the-best-small-cap-asx-stocks-to-buy-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4582","UNI.AU","BK7508","BK7095","EPP","CUV.AU","DVP.AU","BK7067","BK7021"],"gpt_icon":0},{"id":"2529587483","title":"Clinuvel Pharmaceuticals Ltd (CLVLF) (H1 2025) Earnings Call Highlights: Strong Revenue Growth ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2529587483","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529587483?lang=en_us&edition=fundamental","pubTime":"2025-04-22 04:32","pubTimestamp":1745267545,"startTime":"0","endTime":"0","summary":"Sales Growth: Increased by 10.5% to $36 million.Total Revenues: Grew by 21% to $43 million.Expenses Growth: Contained to a modest 2% increase.Profit Before Tax: Rose by 48% to just under $22 million.Profit After Tax: Increased by almost 30% to $14 million.Earnings Per Share: Increased by 27% from $0.22 to $0.28 per share.Net Assets: Strengthened with a 7% increase since June last year.Cash Reserves: Rose by 8% to $198 million.GuruFocus has detected 2 Warning Signs with CLVLF.Clinuvel Pharmaceuticals Ltd  reported a 10.5% increase in sales to $36 million and a 21% rise in total revenues to $43 million.Clinuvel Pharmaceuticals Ltd  maintained a strong balance sheet with a 7% increase in net assets and an 8% rise in cash reserves to $198 million.Clinuvel Pharmaceuticals Ltd  faces competition in recruiting clinical trials for vitiligo, which may require strategic resource deployment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clinuvel-pharmaceuticals-ltd-clvlf-h1-203225350.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["CLVLF","CUV.AU"],"gpt_icon":0},{"id":"2527714507","title":"High Growth Tech Stocks To Watch In April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527714507","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527714507?lang=en_us&edition=fundamental","pubTime":"2025-04-15 03:35","pubTimestamp":1744659336,"startTime":"0","endTime":"0","summary":"The Australian market showed strength on Monday, with the IT sector leading gains by 2.6%, buoyed by positive momentum from Wall Street and a rise in materials driven by higher iron ore and gold prices. In this environment, identifying high growth tech stocks involves looking for companies that are capitalizing on current market trends and demonstrating resilience during earnings season, as they can potentially offer significant opportunities for investors seeking exposure to innovative sectors.Click here to see the full list of 48 stocks from our ASX High Growth Tech and AI Stocks screener.Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and internationally; it has a market cap of A$536.43 million.Operations: Clinuvel Pharmaceuticals generates revenue primarily from its biopharmaceutical sector, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-watch-193536682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["XJO.AU","BK7503","BK7067","IFM.AU","SDR.AU","BK7508","BK7016","XKO.AU","XAO.AU","CUV.AU"],"gpt_icon":0},{"id":"2522235477","title":"Clinuvel Pharmaceuticals to Buy Back Up to 1.5 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2522235477","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522235477?lang=en_us&edition=fundamental","pubTime":"2025-03-27 06:30","pubTimestamp":1743028235,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said it will repurchase a maximum of 1.5 million ordinary fully-paid shares as part of an on-market buyback, according to a Thursday Australian bourse filing.The repurchases are expected to start on April 10 and will run for 12 months, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","XAO.AU","CUV.AU","BK7508","BK7067","XKO.AU"],"gpt_icon":0},{"id":"2522351474","title":"BRIEF-Clinuvel Pharmaceuticals Renews Share Buy-Back Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2522351474","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522351474?lang=en_us&edition=fundamental","pubTime":"2025-03-27 06:04","pubTimestamp":1743026647,"startTime":"0","endTime":"0","summary":"BRIEF-Clinuvel Pharmaceuticals Renews Share Buy-Back ProgramMarch 27 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX:RENEWS SHARE BUY-BACK PROGRAMREPURCHASE OF UP TO 1.5 MILLION ORDINARY SHARESFurther company coverage: CUV.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90ZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2522735111","title":"Clinuvel Pharmaceuticals Ltd - Renews Share Buy-Back Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2522735111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522735111?lang=en_us&edition=fundamental","pubTime":"2025-03-27 06:03","pubTimestamp":1743026594,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90ZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2522351114","title":"Clinuvel Pharmaceuticals Ltd -  Repurchase of up to 1.5 Mln Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2522351114","media":"THOMSON REUTERS","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522351114?lang=en_us&edition=fundamental","pubTime":"2025-03-27 06:03","pubTimestamp":1743026594,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90ZR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2522124298","title":"ASX Market Close: Index flirts with 8000 pts | March 26, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522124298","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522124298?lang=en_us&edition=fundamental","pubTime":"2025-03-26 14:44","pubTimestamp":1742971440,"startTime":"0","endTime":"0","summary":"The ASX closed up 0.7% at 7,999 points.Staples was the best performing sector, up 1.2%, followed by Real Estate, Industrials and Financials, all up around 1.1%.Health Care was the sole sector in the red, down 0.5%.Frontier Energyclosed up 14.8% after progressing to the second stage of its strategic investor process for the Waroona Renewable Energy Project following multiple non-binding indicative offers from potential investors.Delta Lithiumfinished up 2.9% after an update on exploration and permitting at its 100%-owned Mt Ida Gold Project in WesternAustralia’s Eastern Goldfields.Paladin Energy  has wrapped up down 11.6%. Investors have been selling the stock following a not-so-positiveupdateon the Langer Heinrich Mine in Namibia.Sovereign Metals  closed down 16.4% following the completion of an institutional placement today.Lunnon Metalsclosed down 4.3% after completing key mining and exploration surveys in collaboration with the Ngadju People, the traditional owners of the land encom","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-index-flirts-with-8000-pts-march-26-2025-2025-03-26/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7506","BK7060","CUV.AU","BK7095","PDN.AU","LM8.AU","SVM.AU","BK7509","FHE.AU","BK7067","DLI.AU","BK7083","BK7508"],"gpt_icon":0},{"id":"2522863969","title":"ASX Midday Sector Update: Materials Sector Soars, Healthcare Struggles","url":"https://stock-news.laohu8.com/highlight/detail?id=2522863969","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522863969?lang=en_us&edition=fundamental","pubTime":"2025-03-26 10:29","pubTimestamp":1742956181,"startTime":"0","endTime":"0","summary":"Materials stocks jumped 1.24% at midday Wednesday, leading a broad-based rally on the ASX. Australia's consumer price index rose 2.4% in the 12 months to February, following a 2.5% increase in the yea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMH.AU","XJO.AU","XAO.AU","BK4137","CUV.AU","XKO.AU","HCSG","BK7504","BK4585","BK7508","BK7067","BK4544","BK7095","BK4588","ARKG"],"gpt_icon":1},{"id":"2522989091","title":"Why Clinuvel, Orthocell, Vulcan, and Wildcat shares are storming higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2522989091","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522989091?lang=en_us&edition=fundamental","pubTime":"2025-03-26 09:58","pubTimestamp":1742954294,"startTime":"0","endTime":"0","summary":"In afternoon tradeS&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.8% to 8,004.2 points. Four ASX shares that are rising more than","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/26/why-clinuvel-orthocell-vulcan-and-wildcat-shares-are-storming-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7110","WC8.AU","XJO.AU","BK7506","AIS","BK7508","PLS.AU","BK7095","AIS.AU","BK7507","OCC.AU","VUL.AU","CUV.AU","BK7067","BK7504"],"gpt_icon":0},{"id":"2522650198","title":"Clinuvel stroke drug shows ‘positive’ results – but some adverse effects left unclear","url":"https://stock-news.laohu8.com/highlight/detail?id=2522650198","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522650198?lang=en_us&edition=fundamental","pubTime":"2025-03-26 09:53","pubTimestamp":1742953980,"startTime":"0","endTime":"0","summary":"Clinuvel  shares have jumped on Tuesday morning on higher than average volumes as the health care company reported a clinical trial win with its stroke drug, ‘PRENUMBRA’ – chemical name afamelanotide.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.Shares jumped over 2% in Wednesday morning trades in what will be taken as relief by some shareholders given the stock’s declines across the last twelve months.“With the CUV801 and CUV803 studies we have generated a small, but encouraging, data set that demonstrates the drug’s safety profile in patients with strokes of varying degrees of severity, as well as first indications that patients may benefit from treatment,” Clinuvel Chair Prof. Jeffrey Rosenfeld said.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/clinuvel-stroke-drug-shows-positive-results-but-some-adverse-effects-left-unclear-2025-03-26/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2522853345","title":"Clinuvel Pharmaceuticals Reports Positive Study Results for Arterial Ischaemic Stroke Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522853345","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522853345?lang=en_us&edition=fundamental","pubTime":"2025-03-26 08:20","pubTimestamp":1742948413,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said preliminary results from its second clinical study investigating its afamelanotide drug candidate as a treatment for arterial ischaemic stroke were positive, ac","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2520632719","title":"BRIEF-Clinuvel Pharmaceuticals Says CEO Philippe Wolgen To Take Temporary Leave","url":"https://stock-news.laohu8.com/highlight/detail?id=2520632719","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520632719?lang=en_us&edition=fundamental","pubTime":"2025-03-18 09:21","pubTimestamp":1742260873,"startTime":"0","endTime":"0","summary":"BRIEF-Clinuvel Pharmaceuticals Says CEO Philippe Wolgen To Take Temporary LeaveMarch 18 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX:CEO PHILIPPE WOLGEN TO TAKE TEMPORARY LEAVELACHLAN HAY APPOINTED ACTING CEO OF CLINUVELFurther company coverage: CUV.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nFWN3Q00JA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"gpt_icon":0},{"id":"2520680808","title":"Clinuvel Pharmaceuticals' CEO to take Temporary Leave","url":"https://stock-news.laohu8.com/highlight/detail?id=2520680808","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520680808?lang=en_us&edition=fundamental","pubTime":"2025-03-18 06:50","pubTimestamp":1742251809,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  Chief Executive Philippe Wolgen will be on a temporary leave of absence from his full duties due to health reasons, according to a Tuesday filing with the Australian bourse.During Wolgen's absence, Chief Operations Officer Lachlan Hay will serve as acting CEO, with the executive team handling Wolgen's daily responsibilities for up to three months, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2520722684","title":"Clinuvel Pharmaceuticals Ltd - Lachlan Hay Appointed Acting CEO of Clinuvel","url":"https://stock-news.laohu8.com/highlight/detail?id=2520722684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520722684?lang=en_us&edition=fundamental","pubTime":"2025-03-18 06:02","pubTimestamp":1742248950,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nFWN3Q00JA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2520967554","title":"High Growth Tech Stocks In Australia For March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520967554","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520967554?lang=en_us&edition=fundamental","pubTime":"2025-03-17 03:05","pubTimestamp":1742151929,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a turbulent period marked by global trade tensions and fluctuating indices, investors are keeping a keen eye on high-growth tech stocks that have the potential to thrive amid economic uncertainties. In this environment, identifying promising tech companies involves looking for those with innovative solutions and strong adaptability to shifting market dynamics, making them well-positioned to capitalize on emerging opportunities.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/high-growth-tech-stocks-in-australia-for-march-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XAO.AU","BK7067","BK7016","IFM.AU","SDR.AU","XKO.AU","BK7503","BK7508","CUV.AU","XJO.AU"],"gpt_icon":0},{"id":"2516660815","title":"Imugene Appoints CFO; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516660815","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516660815?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:35","pubTimestamp":1741044931,"startTime":"0","endTime":"0","summary":"Imugene  appointed Clinuvel Pharmaceuticals'  former Chief Financial Officer Darren Keamy as CFO, effective immediately, according to a Tuesday filing with the Australian bourse.Keamy will succeed current CFO Mike Tonroe, the filing said.Shares of the pharmaceutical company fell 3% in recent trade,Price : $0.04, Change: $-0.00100, Percent Change: -2.78%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","XKO.AU","XJO.AU","IMU.AU","XAO.AU","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2514890322","title":"Clinuvel Pharmaceuticals Posts Higher Fiscal H1 Earnings, Revenue; Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514890322","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514890322?lang=en_us&edition=fundamental","pubTime":"2025-02-27 08:29","pubTimestamp":1740616182,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  reported Thursday that its earnings per diluted share in the fiscal first half rose to AU$0.28 from AU$0.212 a year earlier.Analysts polled by Visible Alpha were expecting an EPS of AU$0.20.Revenue for the six months ended Dec. 31, 2024, was AU$35.6 million, up from AU$32.3 million in the same period a year earlier. Analysts surveyed by Visible Alpha expected AU$35.6 million.The company's shares rose past 8% in recent Thursday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-09-05","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-09-06","defaultRemindTime":1725494400000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-20","payableDate":"2024-09-06","currency":"AUD","dateTimestamp":1725458400000,"payDate":"2024-09-20"},{"date":"2024-08-29","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724889600000,"name":null,"time":"","dateTimestamp":1724853600000,"actualEps":null},{"date":"2024-02-22","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708556400000,"name":null,"time":"","dateTimestamp":1708520400000,"actualEps":null},{"date":"2023-09-05","symbol":"CUV.AU","amount":0.05,"announcedDate":"2023-08-29","type":"dividend","market":"AU","newRecordDate":"2023-09-06","defaultRemindTime":1693872000000,"name":"Clinuvel Pharmaceuticals Ltd","recordDate":"2023-09-20","payableDate":"2023-09-06","currency":"AUD","dateTimestamp":1693836000000,"payDate":"2023-09-20"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}]}}